88857-57-2

Upstream product

• 92873-08-0 5'Brom-2'-methoxy-trans-stilben-carbonsaeure-⁽²⁾ 
• 94206-66-3 3-(5-bromo-2-methoxy-benzyl)-3H-isobenzofuran-1-one 
• 118-90-1 ortho-methylbenzoic acid 
• 184970-28-3 4-bromo-2-(bromomethyl)-1-methoxybenzene 

Downstream Products

• 685126-64-1 2-{2-[2-(5-bromo-2-methoxy-phenyl)-ethyl]-phenyl}-4-isopropyl-1-methyl-4,5-dihydro-1H-imidazole 
• 685126-59-4 2-{2-[2-(5-bromo-2-methoxy-phenyl)-ethyl]-phenyl}-5-ethyl-1-methyl-4,5-dihydro-1H-imidazole 
• 685126-61-8 2-{2-[2-(5-bromo-2-methoxy-phenyl)-ethyl]-phenyl}-4-ethyl-1-methyl-4,5-dihydro-1H-imidazole 
• 685126-60-7 2-{2-[2-(5-bromo-2-methoxy-phenyl)-ethyl]-phenyl}-1,4,5-trimethyl-4,5-dihydro-1H-imidazole 
• 685126-56-1 2-{2-[2-(5-bromo-2-methoxy-phenyl)-ethyl]-phenyl}-1,4-dimethyl-4,5-dihydro-1H-imidazole 

Relevant academic research and scientific papers

Synthesis and biological evaluation of imidazole-based small molecule antagonists of the melanocortin 4 receptor (MC4-R)

A novel series of imidazole-based small molecule antagonists of the melanocortin 4 receptor (MC4-R) is reported. Members of this series have been identified, which exhibit sub-micromolar binding affinity for the MC4-R, functional potency 100nM, and good oral exposure in rat. Antagonists of the MC4-R are potentially useful in the therapeutic treatment of involuntary weight loss due to advanced age or disease (e.g. cancer or AIDS), an area of large, unmet medical need.